ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Epidemiology and pathogenesis of Neisseria gonorrhoeae infection

Epidemiology and pathogenesis of Neisseria gonorrhoeae infection
Literature review current through: Jan 2024.
This topic last updated: May 08, 2023.

INTRODUCTION — Infection with Neisseria gonorrhoeae is a global problem. In the United States, it is the second most commonly reported communicable disease and the second most prevalent sexually transmitted infection (STI). Symptomatic gonorrhea results in urethritis in males and cervicitis in females. Untreated gonorrhea can lead to epididymitis in males and pelvic inflammatory disease (PID) in females, which can lead to serious sequelae such as infertility, ectopic pregnancy, and chronic pelvic pain. Infrequently, gonococcal infections can become invasive, leading to disseminated gonococcal infections (DGI), which may result in gonococcal arthritis-dermatitis syndrome, suppurative arthritis, endocarditis, and meningitis.

The epidemiology and pathogenesis of gonorrhea will be discussed here. The clinical manifestations, diagnosis, and management of gonococcal infections are discussed in detail elsewhere. (See "Clinical manifestations and diagnosis of Neisseria gonorrhoeae infection in adults and adolescents" and "Cutaneous manifestations of gonorrhea" and "Treatment of uncomplicated gonorrhea (Neisseria gonorrhoeae infection) in adults and adolescents" and "Disseminated gonococcal infection".)

EPIDEMIOLOGY

Global incidence — The precise global burden of N. gonorrhoeae is difficult to establish because of the lack of diagnostic capability and/or reporting systems in many parts of the world. The World Health Organization (WHO) has estimated the global incidence of several sexually transmitted infections (STIs) among individuals aged 15 to 49 years based on data from regions that have good case-based surveillance systems as well as data from population-based studies [1]. In 2020, the estimate for N. gonorrhoeae was 82.4 million cases, a small decrease from 2016 but higher than the goal needed to achieve a 90 percent reduction in the incidence of gonorrhea by 2030 [2].

The WHO African Region had the highest incidence rate, followed by the South-East Asia region [2]. In one review of infections during pregnancy in sub-Saharan Africa, the prevalence of sexually transmitted and reproductive tract infections was comparable with that of malaria [3]. The prevalence of N. gonorrhoeae during pregnancy ranged from 1.5 percent in West and Central Africa to 4.9 percent in East and Southern Africa.

United States

Incidence — Despite a small decrease in the global incidence of gonorrhea in recent years, the incidence of gonorrhea in the United States has been increasing. In 2021, gonorrhea was the second most common notifiable STI in the United States, with 710,151 reported cases [4]. The actual number of cases is likely much higher due to under-reporting of cases, which was exacerbated by surveillance challenges posed by the COVID-19 pandemic, and asymptomatic infections.

The epidemiology of gonococcal infections in the United States has undergone major changes over time. Overall rates declined after the mid-1970s, reaching an all-time low of 98 cases per 100,000 persons in 2009. Since this nadir, the incidence in reported cases has increased annually. The number of cases reported in 2021 reflected a 65 percent increase among females and a 138 percent increase among males compared with 10 years previously [4].

The incidence of gonorrhea has increased among all demographic groups; however, there are important disparities with particularly high rates of infection in specific subpopulations. The highest reported rates of gonococcal infection are seen among adolescents and young adults, certain under-represented racial groups, and persons living in the southeastern United States (figure 1 and figure 2). As examples, in 2021 [4]:

Reported case rates in the United States were highest among males and females ages 20 through 24 years (844 and 873 per 100,000 people, respectively).

Males and females identifying as Black/African American had the highest reported cases of any race. The rate of reported cases by Black/African American males was over ninefold higher than the rate reported by White males (800 versus 85 per 100,000 people). The rate for Black/African American females was over sevenfold higher than for White females (515 versus 72 per 100,000 people). Reasons for the racial disparity in gonorrhea rates are not well understood but may include differences in health services access and utilization, geographic clustering of populations, other interrelated social and economic factors, and sexual partner choices along both socioeconomic and racial lines [5]. In addition, differential reporting by public and private health care providers may magnify the racial differences [6].

Mississippi (428 per 100,000 people), South Dakota (364 per 100,000 people), and Louisiana (354 per 100,000 people) had the highest reported case rates in the United States. These were substantially higher than the case rate reported for the nation as a whole (214 per 100,000 people).

Additional information on the incidence of gonorrhea is available online at: www.cdc.gov/std.

Factors contributing to incidence trends — It is likely that multiple factors contributed to the overall decrease in gonorrhea rates over several decades, leading to the historic low observed in 2009. Screening programs that incorporate on-site antibiotic therapy have been in use since the early 1970s [7]. In addition, a shift in the age distribution of the United States population has meant that a decreasing proportion of people fall into the highest risk age groups [7].

Changes in sexual behavior in response to the human immunodeficiency virus (HIV) epidemic may also be important. Several reports indicated that men who have sex with men (MSM) reduced risky sexual practices in the mid-1980s and had lower rates of rectal gonorrhea [8]. Although evidence for sexual behavior risk-reduction in response to the HIV epidemic among heterosexuals is limited, increased condom use has been documented [9].

However, the trend toward safer sexual practices among MSM has been reversing. Gonorrhea in MSM accounts for a rapidly increasing proportion of all gonorrhea cases; in 2020, approximately a third of all cases of gonorrhea occurred among MSM [4]. The increase is consistent with increases in the numbers of MSM engaging in high-risk sexual behaviors [10].

Risk factors — Risk factors and risk markers for gonorrhea include a recent new sexual partner, multiple sexual partners, being unmarried, young age, of an under-represented ethnic population, low educational and socioeconomic levels, substance abuse, and a history of previous gonorrhea [11-13]. Geographic clustering of gonorrhea coincides with geographic clustering of many of these risk markers [14]. Combinations of these markers have been used to identify persons for screening for asymptomatic gonococcal infection [12].

Among MSM with high-risk sexual behavior, the incidence of gonorrhea is quite high. In a study of nearly 3000 MSM in Australia who were initiating pre-exposure prophylaxis for HIV, the incidence of new N. gonorrhoeae infections (urogenital, rectal, and pharyngeal) was 39 cases per 100 person-years [15].

Rate of infection after exposure — Data on the attack rate after exposure to an infected partner are somewhat mixed. In one study of 26 females with recent exposure to N. gonorrhoeae, the attack rate was 50 percent following one documented exposure to an infected male sexual partner and increased to 93 percent with repeated exposures [16]. In contrast, a subsequent study of 76 females exposed to either chlamydia or gonorrhea found a transmission rate of 73 percent among the 45 females with exposure to gonorrhea only, and the number of encounters did not increase the risk [17].

Association with HIV — N. gonorrhoeae has an important epidemiologic relationship with HIV. First, the acquisition of gonococcal infection implies risky sexual behavior that is in turn a risk factor for HIV infection. Second, the presence of gonococcal infection appears to facilitate both the transmission and acquisition of HIV [18,19], and conversely, the presence of HIV infection is associated with increased acquisition of N. gonorrhoeae [20].

In a study of males with HIV in Malawi, for example, HIV RNA concentrations in semen were eightfold higher among those with urethritis, particularly due to gonorrhea, compared to those without [19]. Furthermore, treatment of the urethritis lowered HIV ribonucleic acid (RNA) levels by two-thirds. Molecular mechanisms contributing to enhanced HIV transmission may include activation of HIV-infected CD4 cells by N. gonorrhoeae, resulting in increased HIV expression and viral production [21]. Additionally, gonococcal infection during HIV acquisition is associated with an altered HIV specific CD8 cell response [22].

Additionally, among HIV-uninfected individuals, particularly MSM, diagnosis of gonococcal infection is associated with subsequent HIV acquisition [23,24]. Thus, this could serve as a marker for identifying potential candidates among MSM for pre-exposure prophylaxis against HIV. (See "HIV pre-exposure prophylaxis".)

Epidemiological tools for gonorrhea strain differentiation — Infections with N. gonorrhoeae are caused by many different strains. Although not part of the standard clinical diagnostic armamentarium, strain-typing techniques are employed for epidemiologic purposes to investigate outbreaks, antibiotic resistance patterns, and transmission networks, and for medicolegal cases. Both microbiologic (phenotype) and molecular (genetic sequence type) methods to differentiate strains are used.

Phenotypic methods include:

Serotyping – using monoclonal antibodies that can distinguish variations in the major outer membrane porin protein (protein I, or PorB).

Auxotyping – discriminating strains based on nutrient growth requirements.

Antimicrobial – using resistance profile including both plasmid- and genome-based resistance.

Monoclonal antibodies are not widely available, some strains are non-typable, and poor reproducibility of serotyping has been shown [25]. Nonetheless, these phenotypic methods have demonstrated remarkable strain diversity within and among geographic areas, with a small number of auxotype/serotype classes predominating in most communities [26]. The association of particular strains with disseminated disease and observed patterns of importation and endemic transmission of gonococcal strains are based on phenotypic studies. These methods are generally used in public health and reference laboratories.

Molecular characterization methods have allowed for more accurate and finer discrimination of strains. They have been used in outbreak investigations and to identify sexual partner pairs or transmission networks [27-30]. These typing methods have also been used in studies of antimicrobial resistance [31]. Such molecular methods include:

Pulsed-field gel electrophoresis, ribotyping, ribosomal-deoxyribonucleic acid (DNA) restriction analysis, arbitrarily primed polymerase chain reaction (PCR) and fluorescent amplified fragment length polymorphism analyses, and opa typing (based on restriction fragment length polymorphism of PCR amplicons of the opa locus). These are genetic typing methods that differentiate strains based on electrophoresis banding patterns. These methods are used with epidemiologic data to study transmission patterns and identify sexual networks, but they are difficult to standardize for inter-laboratory comparisons.

DNA sequencing of outer membrane protein genes, typically the porB gene alone or in combination with the iron binding protein gene tbpB (NG-MAST) [32].

Multi-locus sequence typing (MLST), based on sequence analysis of a panel of housekeeping genes [33,34].

Whole-genome sequencing [35,36].

Epidemiology of antimicrobial resistance — Over time, N. gonorrhoeae has developed increasing minimum inhibitory concentrations (ie, decreasing susceptibility) followed by frank resistance to the antimicrobial classes most commonly used for therapy, thus progressively reducing available therapeutic options [37]. Domestic and international gonococcal surveillance efforts have demonstrated increased resistance worldwide to multiple classes of antibiotics, including penicillins, tetracyclines, macrolides, and fluoroquinolones, with documented cross-resistance [38-42]. An especially alarming trend in N. gonorrhoeae drug resistance has been the progressive decrease in susceptibility to the cephalosporins [43], and the identification of high-level ceftriaxone-resistance [44], heralding the potential for untreatable gonorrhea in the near future. Further details of N. gonorrhoeae drug resistance are discussed elsewhere. (See "Treatment of uncomplicated gonorrhea (Neisseria gonorrhoeae infection) in adults and adolescents", section on 'Antibiotic resistance'.)

Individuals who are repeatedly infected with N. gonorrhoeae (core groups) play an important role in maintaining gonococcal transmission within communities and in the development and spread of antibiotic-resistant gonorrhea [45,46]. MSM appear to have an increased rate of gonococcal infection due to a higher prevalence of resistant isolates than men who have sex exclusively with women (MSW), likely because MSM sexual networks are more likely to have circulating antibiotic-resistant strains than MSW networks [47].

PATHOGENESIS — N. gonorrhoeae is strictly a human pathogen with no known animal or environmental reservoir. Its success as a human pathogen is the combined result of several factors: an impressive array of virulence factors that allow this bacterium to gain a foothold into and adapt to the disparate and embryologically distinct male and female genital tracts, a chameleon-like ability to undergo high-frequency antigenic and phase variation of surface structures leading to clonal variation, and the ability to subvert the immune system. When gonococcal infections are unrecognized or left untreated, they can become chronic, and reinfections are common. N. gonorrhoeae is also adept at quickly developing resistance to antibiotics, which could ultimately lead to untreatable infections.

Gonococcal infection encompasses four specific stages:

Attachment to the mucosal cell surface

Local penetration or invasion

Local proliferation

Local inflammatory response or systemic dissemination

Adhesins used for attachment — Initial attachment of gonococci to the surface of epithelial cells is mediated by type IV pili, which are long, hair-like appendages radiating from the bacterial surface (figure 3). Pili can be extended or retracted; retraction allows intimate attachment to host cells. In addition to host-cell attachment, gonococcal pili also play a role in bacterial aggregation, DNA transformation, twitching motility, and protection from neutrophil killing [48-51]. PilE is the most abundant protein subunit involved in the pilin biogenesis and deletion of the pilE gene results in a non-piliated phenotype [52].

Human challenge studies suggest that pili are important for infection and that anti-pilin antibodies can block binding [53]. Gonococcal pili however are subject to high frequency antigenic variation as a result of DNA-recombination events between pilE and several silent and antigenically-distinct pilin genes (pilS) [54,55]. This high frequency antigenic variation was likely the reason a purified gonococcal pilin vaccine tested in humans was unable to provide protection from disease [56].

Other outer membrane structures involved in gonococci attachment include:

PilC proteinsN. gonorrhoeae possesses two pilC genes: pilC1 and pilC2. PilC1 and pilC2 have thus far been demonstrated to function interchangeably. PilC is typically found at the tip of the type IV pilus, but also resides in the bacterial outer membrane [57,58]. PilC is considered the main pilus adhesin as pilC mutants fail to bind to epithelial cells [59], and purified pilC bound to epithelial cells competes with and blocks pilus-mediated gonococcal adherence [57,60]. The host cell receptor for pilC remains to be elucidated. Some data suggest that the human complement cell receptor (CD46) may be the elusive gonococcal pilus receptor [61,62], however conflicting data indicate that host cell attachment is independent of CD46 [63,64]. PilC also plays a role in DNA uptake and pilus retraction [65,66].

Opa (opacity-associated proteins or protein II) – These are a family of 11 or 12 related but antigenically- and phenotypically-distinct proteins that increase colony opacity of N. gonorrhoeae [67]. Opa proteins mediate intimate binding with leukocytes, epithelial, and endothelial cells [68]. Opa expression appears to be critical for in vivo survival as gonococcal isolates obtained from natural infections are predominately Opa-positive, except for isolates obtained during menses [68]. Gonococcal isolates recovered from males experimentally-infected with Opa-negative strains were positive for Opa expression [67,69], suggesting a strong selective pressure for Opa expression in vivo. Opa proteins undergo frequent phase variation due to pentameric sequence repeats within the signal sequence coding region that can result in slip-strand mispairing frameshifts during DNA replication [70]. As a result, within a population of gonococci, Opa expression can be highly variable from zero, one, to multiple Opa variants expressed per bacterium [68]. Most Opa proteins have tropism to the carcinoembryonic antigen cell adhesion molecule (CEACAM) family found on a variety of cell types [68]. Cellular expression of different members of the CEACAM family may explain preferential binding of gonococci to particular cells, since Opa variants exhibit different binding specificities for various CEACAM family members [71,72]. A smaller number of Opa proteins have shown tropism to heparin sulphate proteoglycans (HSPGs), vitronectin, and fibronectin [73,74].

PorB – PorB is the most abundant outer membrane protein expressed by N. gonorrhoeae and functions as a pore, allowing movement of ions and nutrients into the bacterial periplasm [75]. N. gonorrhoeae strains possess one of two allelic variants of PorB, either PorB1A or PorB1B, which share about 80 percent nucleotide sequence similarity [76]. PorB1A-expressing strains are often associated with disseminated gonococcal infection (DGI), are more serum-resistant, and invade cells to a greater degree than PorB1B-expressing strains [77]. PorB binds to the human complement receptor 3 (CR3), which is expressed in the female reproductive tract [78].

Gonococcal lipooligosaccharide (LOS) – LOS binds to human asialoglycoprotein receptor (ASGP-R) expressed on a human hepatoma cell line (HepG2), urethral epithelial cells, and sperm cells [79-81]. The ability of the gonococcus to bind to sperm cells has been postulated to contribute to transmission of gonorrhea from infected males to uninfected sexual partners [80].

Gonococcal ribosomal protein L12 – This is a membrane-associated surface protein that is a structural homologue to the fetal hormone human chorionic gonadotropin (hCG), an essential pregnancy hormone [82,83]. Expression of gonococcal L12 allows attachment to and invasion of an endometrial cell line via interaction with the lutropin receptor (LHr), the cognate receptor for hCG [82,84]. A potential mechanism of invasive disease is that the gonococcal L12 may "hijack" the LHr receptor expressed in the endometrium and fallopian tubes, and ultimately transcytose to the sub-mucosal tissues leading to pelvic inflammatory disease (PID) or disseminated gonococcal infection (DGI) in females. This hypothesis is consistent with the clinical observation that in females, PID and DGI tend to occur during the first week of menses [85,86] when LHr expression in the endometrium and fallopian tubes is highest [87,88].

N. gonorrhoeae outer membrane protein A (Ng-OmpA) – Ng-OmpA is a newly identified adhesin and invasin. A gonococcal strain unable to express Ng-OmpA was significantly attenuated in a mouse colonization model, and gonococcal binding and invasion of cervical and endometrial cell lines was diminished with ng-ompA mutants [89].

MetQ – This is a newly characterized methionine-binding component of an adenosine triphosphate-binding cassette (ABC) transporter shown to contribute to adherence of gonococci to cervical epithelial cells [90].

Local invasion — In clinical specimens from individuals with gonorrhea, intracellular gonococci are found in both epithelial cells and neutrophils [78], and the gonococcus is able to multiply and divide intracellularly [91,92]. Invasion into host cells may protect the gonococcus from the harsh mucosal environment and immune effectors. Local invasion requires intimate host cell contact. Potential molecular mechanisms of gonococcal invasion strategies have been elucidated in vitro using various cell lines:

Binding and invasion of urethral epithelial cell lines involves both pili and LOS. In this model, initial binding to the host cell occurs through the interaction of pili with the I-domain of B1-integrins, followed by closer association through LOS interactions with host cell ASGP-R [79,93]. The bound bacteria are internalized following host cell membrane pedestal formation, in an actin- and clathrin-dependent process [94-96].

Invasion of cervical epithelial cell lines involves gonococcal binding to the host cell complement receptor type 3 (CR3). This is a cooperative interaction initiated by the binding of pili to the I-domain of CR3 [97]. Complement component C3b binds to the lipid A core of the gonococcal LOS and is rapidly inactivated to iC3b by PorB- or LOS-bound factor H [98]. Gonococcal-bound iC3b and PorB also bind to the I-domain of CR3 strengthening the CR3 interaction [97]. This coordinated engagement of the CR3 causes extensive rearrangement of the host cell actin, resulting in large protrusions called ruffles [99]. Membrane ruffling subsequently allows for the internalization of gonococci in large vacuoles called macropinosomes where they survive and multiply within the cell [100,101].

Opa expression plays an important role in invasion as well as host cell binding. Opa interaction with host cell CEACAMs mediates internalization [72,102-104]. Recombinant Escherichia coli strains expressing gonococcal Opa proteins were bound and internalized by human cervical and endometrial cell lines more efficiently than the wild-type E. coli strains [105,106], demonstrating Opa expression by itself can be sufficient for invasion of host cells.

PorB also plays a role in host cell invasion. As mentioned above, DGI is associated most commonly with N. gonorrhoeae strains expressing the PorBIA allele [107]. Epithelial cell invasion in vitro was demonstrated with strains expressing PorBIA but not PorBIB in a phosphate-dependent manner [77]. The host cell scavenger receptor (SREC-I) has been identified as the PorBIA ligand, and expression of SREC-I is sufficient for gonococcal PorBIA invasion of both epithelial and endothelial cells [108]. In addition, a recombinant E. coli strain expressing gonococcal PorBIA was 500-fold more invasive than wild-type E. coli in a human fallopian organ-culture model demonstrating expression of PorBIA is sufficient for invasion [109].

Dissemination — Typically, N. gonorrhoeae causes localized urogenital infections; however, in rare cases, disseminated infections can occur [86]. Gonococcal strains are classified as either serum-sensitive or serum-resistant based upon their sensitivity to killing by normal human sera via the activation of complement and the deposition of terminal complement components on the bacterial surface [110,111]. Dissemination can occur when strains are serum resistant.

PorB1A and some variants of PorB1B bind to both the classical and alternative complement down-regulatory proteins C4bp and factor H, rendering strains with these porin types serum-resistant [112,113]. Gonococci can also sialylate their LOS using host-derived cytidine monophospho-N-acetylneuraminic acid (CMP-NANA) [114]. Sialylated LOS increases factor H binding substantially, resulting in serum resistance [115]. Gonococcal LOS sialylation has been demonstrated in gonorrhea urethral exudates [116].

Adaptation to evade host immunity — In order for N. gonorrhoeae to survive the host immune response, it has developed complex strategies to avoid host defense mechanisms. Examples of these strategies include:

Antigenic and phase variation of Opa, Pil, and LOS [70,117,118]. As an example, multiple pilin antigenic variants are produced during an infection, which helps to avoid antibody neutralization to one specific pilin variant [118].

Masking of gonococcal antigens (sialylation of LOS), which prevents the binding of bactericidal antibodies to surface targets [115,119,120].

Molecular mimicry, as demonstrated by the similarity of terminal LOS sugars to host glycolipids which may aid in immune evasion [121].

Release of IgA1 proteases that recognizes and cleaves both serum and secretory IgA [122]. The role of IgA protease in gonococcal pathogenesis has yet to be fully determined. A mutant gonococcal strain unable to produce IgA protease was limited in intracellular growth in vitro cell culture compared to the wild-type strain, however, another IgA protease mutant was able to cause urethritis in an experimental male challenge model [123,124]. IgA protease may play a larger role in female infections that has yet to be elucidated.

Expression of Neisseria Adhesin Complex Protein (ACP) inhibits human lysozyme activity [125]. Lysozymes are an important component of innate immunity that hydrolyze bacterial cell wall peptidoglycan, resulting in bacteriolysis. Inhibition of lysozyme activity may contribute to host colonization.

Blocking antibodies elicited to the reduction modifiable protein (Rmp). Rmp is physically associated with PorB on the outer membrane of gonococci and is highly immunogenic eliciting noncomplement-fixing antibodies. Antibodies directed against Rmp bind to the PorB-Rmp complex and block the effective deposition of complement-fixing anti-PorB and anti-LOS antibodies [110,126]. Compatible with these experimental findings is the clinical observation that females infected with N. gonorrhoeae who produced Rmp antibodies have an increased risk of salpingitis [127,128].

Dampening the host immune response. One of the hallmarks of gonococcal infection is that it does not induce protective immunity. Following infection, females have limited local and systemic cytokine and antibody responses [129,130]. In vitro studies have shed some light on how the gonococcus is able to subvert both innate and adaptive arms of the immune system. The gonococcus can survive in neutrophils and macrophages by preventing the formation of degradative phagolysosomes. In addition, gonococci can cause cellular death and upregulation of immunoregulatory cytokines [131-134]. Gonococcal-exposed antigen-presenting cells (dendritic cells and macrophages) fail to elicit antigen-induced CD4 cell proliferation and induce immunosuppressive properties [132-135]. Gonococci-expressing Opa proteins that bind to CEACAM1 down-regulate activated CD4 cells and inhibit B-cell antibody production [136,137].

In a mouse-model of gonorrhea [138], infection induces immunoregulatory cytokines, transforming growth factor beta (TGF-beta) and interleukin 10 (IL-10), as well as type 1 regulatory T cells (Tr1), which together suppress the adaptive immune response [139,140]. Mice treated with antibodies that neutralize TGF-beta and/or IL-10 during infection cleared gonococci more rapidly and developed immunity against a secondary challenge [139-141]. Administration of microencapsulated interleukin 12 (IL-12), a proinflammatory cytokine and strong inducer of cellular immunity, during mouse gonococcal vaginal infection led to faster clearance, protection against reinfection, and the development of anti-gonococcal antibodies [142]. These data raise the possibility of investigating immune modulators, such as IL-12 as novel therapeutic strategies, and may provide new insights into the development of effective vaccines to prevent gonorrhea.

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Beyond the Basics topic (see "Patient education: Gonorrhea (Beyond the Basics)")

SUMMARY

Incidence – Infection with Neisseria gonorrhoeae is a global problem, although the precise burden is difficult to establish. In the United States, the highest reported rates of gonococcal infection are seen among adolescents and young adults (figure 1), ethnic under-represented populations, and persons living in the southeastern states (figure 2). The actual burden of gonorrhea is likely underestimated due to under-reporting and asymptomatic infections. (See 'Global incidence' above and 'United States' above.)

Risk factors – Risk factors for gonorrhea include a new sexual partner, multiple sexual partners, being unmarried, young age, of an under-represented ethnic population, low educational and socioeconomic levels, history of substance abuse, and history of a previous episode of gonorrhea. (See 'Risk factors' above.)

Drug resistance – Over time, N. gonorrhoeae has developed decreasing susceptibility followed by frank resistance to the antimicrobial classes most commonly used for therapy, thus progressively reducing available therapeutic options. The prevalence of N. gonorrhoeae drug resistance is discussed elsewhere. (See "Treatment of uncomplicated gonorrhea (Neisseria gonorrhoeae infection) in adults and adolescents", section on 'Antibiotic resistance'.)

Pathogenesis of infection – Infection with N. gonorrhoeae encompasses four specific stages: local attachment, invasion, dissemination, and evasion of host immunity. Various outer membrane structures are involved in each of these stages (figure 3). (See 'Pathogenesis' above.)

ACKNOWLEDGMENTS — The views expressed in this topic are those of the authors and do not reflect the official views or policy of the United States Government or its components.

The UpToDate editorial staff acknowledges Gregory A Price, PhD and Peter Leone, MD, who contributed to earlier versions of this topic review.

  1. Fact Sheet - Sexually Transmitted Infections (STIs). World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis) (Accessed on September 30, 2022).
  2. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. www.who.int/publications/i/item/9789240027077 (Accessed on December 22, 2022).
  3. Chico RM, Mayaud P, Ariti C, et al. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. JAMA 2012; 307:2079.
  4. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2021. https://www.cdc.gov/std/statistics/2021/default.htm (Accessed on April 28, 2023).
  5. Toomey KE, Moran JS, Rafferty MP, Beckett GA. Epidemiological considerations of sexually transmitted diseases in underserved populations. Infect Dis Clin North Am 1993; 7:739.
  6. Fox KK, del Rio C, Holmes KK, et al. Gonorrhea in the HIV era: a reversal in trends among men who have sex with men. Am J Public Health 2001; 91:959.
  7. Fox KK, Whittington WL, Levine WC, et al. Gonorrhea in the United States, 1981-1996. Demographic and geographic trends. Sex Transm Dis 1998; 25:386.
  8. Handsfield HH. Decreasing incidence of gonorrhea in homosexually active men--minimal effect on risk of AIDS. West J Med 1985; 143:469.
  9. Moran JS, Janes HR, Peterman TA, Stone KM. Increase in condom sales following AIDS education and publicity, United States. Am J Public Health 1990; 80:607.
  10. Hess KL, Crepaz N, Rose C, et al. Trends in Sexual Behavior Among Men Who have Sex with Men (MSM) in High-Income Countries, 1990-2013: A Systematic Review. AIDS Behav 2017; 21:2811.
  11. Hook EW 3rd, Reichart CA, Upchurch DM, et al. Comparative behavioral epidemiology of gonococcal and chlamydial infections among patients attending a Baltimore, Maryland, sexually transmitted disease clinic. Am J Epidemiol 1992; 136:662.
  12. Mertz KJ, Levine WC, Mosure DJ, et al. Screening women for gonorrhea: demographic screening criteria for general clinical use. Am J Public Health 1997; 87:1535.
  13. Klausner JD, Barrett DC, Dithmer D, et al. Risk factors for repeated gonococcal infections: San Francisco, 1990-1992. J Infect Dis 1998; 177:1766.
  14. Ellen JM, Hessol NA, Kohn RP, Bolan GA. An investigation of geographic clustering of repeat cases of gonorrhea and chlamydial infection in San Francisco, 1989-1993: evidence for core groups. J Infect Dis 1997; 175:1519.
  15. Traeger MW, Cornelisse VJ, Asselin J, et al. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. JAMA 2019; 321:1380.
  16. Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 1983; 250:3205.
  17. Lin JS, Donegan SP, Heeren TC, et al. Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. J Infect Dis 1998; 178:1707.
  18. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: Results from a cohort study. AIDS 1993; 7:95.
  19. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997; 349:1868.
  20. McClelland RS, Lavreys L, Katingima C, et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis 2005; 191:333.
  21. Malott RJ, Keller BO, Gaudet RG, et al. Neisseria gonorrhoeae-derived heptose elicits an innate immune response and drives HIV-1 expression. Proc Natl Acad Sci U S A 2013; 110:10234.
  22. Sheung A, Rebbapragada A, Shin LY, et al. Mucosal Neisseria gonorrhoeae coinfection during HIV acquisition is associated with enhanced systemic HIV-specific CD8 T-cell responses. AIDS 2008; 22:1729.
  23. Llata E, Braxton J, Asbel L, et al. New Human Immunodeficiency Virus Diagnoses Among Men Who Have Sex With Men Attending Sexually Transmitted Disease Clinics, STD Surveillance Network, January 2010 to June 2013. Sex Transm Dis 2018; 45:577.
  24. Katz DA, Dombrowski JC, Bell TR, et al. HIV Incidence Among Men Who Have Sex With Men After Diagnosis With Sexually Transmitted Infections. Sex Transm Dis 2016; 43:249.
  25. Unemo M, Olcén P, Albert J, Fredlund H. Comparison of serologic and genetic porB-based typing of Neisseria gonorrhoeae: consequences for future characterization. J Clin Microbiol 2003; 41:4141.
  26. Hook EW 3rd, Judson FN, Handsfield HH, et al. Auxotype/serovar diversity and antimicrobial resistance of Neisseria gonorrhoeae in two mid-sized American cities. Sex Transm Dis 1987; 14:141.
  27. Kilmarx PH, Knapp JS, Xia M, et al. Intercity spread of gonococci with decreased susceptibility to fluoroquinolones: a unique focus in the United States. J Infect Dis 1998; 177:677.
  28. O'Rourke M, Ison CA, Renton AM, Spratt BG. Opa-typing: a high-resolution tool for studying the epidemiology of gonorrhoea. Mol Microbiol 1995; 17:865.
  29. Ward H, Ison CA, Day SE, et al. A prospective social and molecular investigation of gonococcal transmission. Lancet 2000; 356:1812.
  30. Heymans R, A Matser A, Bruisten SM, et al. Distinct Neisseria gonorrhoeae transmission networks among men who have sex with men in Amsterdam, The Netherlands. J Infect Dis 2012; 206:596.
  31. Unemo M, Dillon JA. Review and international recommendation of methods for typing neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology. Clin Microbiol Rev 2011; 24:447.
  32. Martin IM, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189:1497.
  33. Bennett JS, Jolley KA, Sparling PF, et al. Species status of Neisseria gonorrhoeae: evolutionary and epidemiological inferences from multilocus sequence typing. BMC Biol 2007; 5:35.
  34. Demczuk W, Lynch T, Martin I, et al. Whole-genome phylogenomic heterogeneity of Neisseria gonorrhoeae isolates with decreased cephalosporin susceptibility collected in Canada between 1989 and 2013. J Clin Microbiol 2015; 53:191.
  35. Singh R, Kusalik A, Dillon JR. Bioinformatics tools used for whole-genome sequencing analysis of Neisseria gonorrhoeae: a literature review. Brief Funct Genomics 2022; 21:78.
  36. Sánchez-Busó L, Cole MJ, Spiteri G, et al. Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study. Lancet Microbe 2022; 3:e452.
  37. Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012; 88:6.
  38. Centers for Disease Control and Prevention (CDC). Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011; 60:873.
  39. European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe - 2010. ECDC, Stockholm, 2012.
  40. Ray K, Bala M, Kumari S, Narain JP. Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview. Sex Transm Dis 2005; 32:178.
  41. Australian Gonococcal Surveillance Programme annual reports. http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-annlrpt-gonoanrep.htm (Accessed on November 01, 2014).
  42. Vandepitte J, Hughes P, Matovu G, et al. High prevalence of ciprofloxacin-resistant gonorrhea among female sex workers in Kampala, Uganda (2008-2009). Sex Transm Dis 2014; 41:233.
  43. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401.
  44. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538.
  45. Chan CH, McCabe CJ, Fisman DN. Core groups, antimicrobial resistance and rebound in gonorrhoea in North America. Sex Transm Infect 2012; 88:200.
  46. Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N gonorrhoeae. Sex Transm Infect 2013; 89 Suppl 4:iv47.
  47. Kirkcaldy RD, Zaidi A, Hook EW 3rd, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013; 158:321.
  48. Sparling PF. Genetic transformation of Neisseria gonorrhoeae to streptomycin resistance. J Bacteriol 1966; 92:1364.
  49. Stohl EA, Dale EM, Criss AK, Seifert HS. Neisseria gonorrhoeae metalloprotease NGO1686 is required for full piliation, and piliation is required for resistance to H2O2- and neutrophil-mediated killing. MBio 2013; 4.
  50. Swanson J. Studies on gonococcus infection. IV. Pili: their role in attachment of gonococci to tissue culture cells. J Exp Med 1973; 137:571.
  51. Wolfgang M, Lauer P, Park HS, et al. PilT mutations lead to simultaneous defects in competence for natural transformation and twitching motility in piliated Neisseria gonorrhoeae. Mol Microbiol 1998; 29:321.
  52. Seifert HS, Ajioka RS, Marchal C, et al. DNA transformation leads to pilin antigenic variation in Neisseria gonorrhoeae. Nature 1988; 336:392.
  53. Rothbard JB, Fernandez R, Wang L, et al. Antibodies to peptides corresponding to a conserved sequence of gonococcal pilins block bacterial adhesion. Proc Natl Acad Sci U S A 1985; 82:915.
  54. Criss AK, Kline KA, Seifert HS. The frequency and rate of pilin antigenic variation in Neisseria gonorrhoeae. Mol Microbiol 2005; 58:510.
  55. Hill SA, Davies JK. Pilin gene variation in Neisseria gonorrhoeae: reassessing the old paradigms. FEMS Microbiol Rev 2009; 33:521.
  56. Boslego JW, Tramont EC, Chung RC, et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 1991; 9:154.
  57. Rudel T, Scheurerpflug I, Meyer TF. Neisseria PilC protein identified as type-4 pilus tip-located adhesin. Nature 1995; 373:357.
  58. Rahman M, Källström H, Normark S, Jonsson AB. PilC of pathogenic Neisseria is associated with the bacterial cell surface. Mol Microbiol 1997; 25:11.
  59. Rudel T, Boxberger HJ, Meyer TF. Pilus biogenesis and epithelial cell adherence of Neisseria gonorrhoeae pilC double knock-out mutants. Mol Microbiol 1995; 17:1057.
  60. Scheuerpflug I, Rudel T, Ryll R, et al. Roles of PilC and PilE proteins in pilus-mediated adherence of Neisseria gonorrhoeae and Neisseria meningitidis to human erythrocytes and endothelial and epithelial cells. Infect Immun 1999; 67:834.
  61. Källström H, Blackmer Gill D, Albiger B, et al. Attachment of Neisseria gonorrhoeae to the cellular pilus receptor CD46: identification of domains important for bacterial adherence. Cell Microbiol 2001; 3:133.
  62. Källström H, Liszewski MK, Atkinson JP, Jonsson AB. Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol 1997; 25:639.
  63. Kirchner M, Heuer D, Meyer TF. CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. Infect Immun 2005; 73:3072.
  64. Tobiason DM, Seifert HS. Inverse relationship between pilus-mediated gonococcal adherence and surface expression of the pilus receptor, CD46. Microbiology 2001; 147:2333.
  65. Morand PC, Bille E, Morelle S, et al. Type IV pilus retraction in pathogenic Neisseria is regulated by the PilC proteins. EMBO J 2004; 23:2009.
  66. Rudel T, Facius D, Barten R, et al. Role of pili and the phase-variable PilC protein in natural competence for transformation of Neisseria gonorrhoeae. Proc Natl Acad Sci U S A 1995; 92:7986.
  67. Swanson J, Barrera O, Sola J, Boslego J. Expression of outer membrane protein II by gonococci in experimental gonorrhea. J Exp Med 1988; 168:2121.
  68. Sadarangani M, Pollard AJ, Gray-Owen SD. Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev 2011; 35:498.
  69. Jerse AE, Cohen MS, Drown PM, et al. Multiple gonococcal opacity proteins are expressed during experimental urethral infection in the male. J Exp Med 1994; 179:911.
  70. Stern A, Brown M, Nickel P, Meyer TF. Opacity genes in Neisseria gonorrhoeae: control of phase and antigenic variation. Cell 1986; 47:61.
  71. Virji M, Watt SM, Barker S, et al. The N-domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Mol Microbiol 1996; 22:929.
  72. Bos MP, Grunert F, Belland RJ. Differential recognition of members of the carcinoembryonic antigen family by Opa variants of Neisseria gonorrhoeae. Infect Immun 1997; 65:2353.
  73. Chen T, Belland RJ, Wilson J, Swanson J. Adherence of pilus- Opa+ gonococci to epithelial cells in vitro involves heparan sulfate. J Exp Med 1995; 182:511.
  74. van Putten JP, Paul SM. Binding of syndecan-like cell surface proteoglycan receptors is required for Neisseria gonorrhoeae entry into human mucosal cells. EMBO J 1995; 14:2144.
  75. Young JD, Blake M, Mauro A, Cohn ZA. Properties of the major outer membrane protein from Neisseria gonorrhoeae incorporated into model lipid membranes. Proc Natl Acad Sci U S A 1983; 80:3831.
  76. Fudyk TC, Maclean IW, Simonsen JN, et al. Genetic diversity and mosaicism at the por locus of Neisseria gonorrhoeae. J Bacteriol 1999; 181:5591.
  77. van Putten JP, Duensing TD, Carlson J. Gonococcal invasion of epithelial cells driven by P.IA, a bacterial ion channel with GTP binding properties. J Exp Med 1998; 188:941.
  78. Edwards JL, Butler EK. The Pathobiology of Neisseria gonorrhoeae Lower Female Genital Tract Infection. Front Microbiol 2011; 2:102.
  79. Harvey HA, Jennings MP, Campbell CA, et al. Receptor-mediated endocytosis of Neisseria gonorrhoeae into primary human urethral epithelial cells: the role of the asialoglycoprotein receptor. Mol Microbiol 2001; 42:659.
  80. Harvey HA, Porat N, Campbell CA, et al. Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm. Mol Microbiol 2000; 36:1059.
  81. Porat N, Apicella MA, Blake MS. Neisseria gonorrhoeae utilizes and enhances the biosynthesis of the asialoglycoprotein receptor expressed on the surface of the hepatic HepG2 cell line. Infect Immun 1995; 63:1498.
  82. Spence JM, Clark VL. Role of ribosomal protein L12 in gonococcal invasion of Hec1B cells. Infect Immun 2000; 68:5002.
  83. Tsampalas M, Gridelet V, Berndt S, et al. Human chorionic gonadotropin: a hormone with immunological and angiogenic properties. J Reprod Immunol 2010; 85:93.
  84. Spence JM, Chen JC, Clark VL. A proposed role for the lutropin receptor in contact-inducible gonococcal invasion of Hec1B cells. Infect Immun 1997; 65:3736.
  85. Nolan GH, Osborne N. Gonococcal infections in the female. Obstet Gynecol 1973; 42:156.
  86. Rice PA. Gonococcal arthritis (disseminated gonococcal infection). Infect Dis Clin North Am 2005; 19:853.
  87. Lei ZM, Reshef E, Rao V. The expression of human chorionic gonadotropin/luteinizing hormone receptors in human endometrial and myometrial blood vessels. J Clin Endocrinol Metab 1992; 75:651.
  88. Reshef E, Lei ZM, Rao CV, et al. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990; 70:421.
  89. Serino L, Nesta B, Leuzzi R, et al. Identification of a new OmpA-like protein in Neisseria gonorrhoeae involved in the binding to human epithelial cells and in vivo colonization. Mol Microbiol 2007; 64:1391.
  90. Semchenko EA, Day CJ, Seib KL. MetQ of Neisseria gonorrhoeae Is a Surface-Expressed Antigen That Elicits Bactericidal and Functional Blocking Antibodies. Infect Immun 2017; 85.
  91. McGee ZA, Johnson AP, Taylor-Robinson D. Pathogenic mechanisms of Neisseria gonorrhoeae: observations on damage to human fallopian tubes in organ culture by gonococci of colony type 1 or type 4. J Infect Dis 1981; 143:413.
  92. McGee ZA, Stephens DS, Hoffman LH, et al. Mechanisms of mucosal invasion by pathogenic Neisseria. Rev Infect Dis 1983; 5 Suppl 4:S708.
  93. Edwards JL, Apicella MA. I-domain-containing integrins serve as pilus receptors for Neisseria gonorrhoeae adherence to human epithelial cells. Cell Microbiol 2005; 7:1197.
  94. Apicella MA, Ketterer M, Lee FK, et al. The pathogenesis of gonococcal urethritis in men: confocal and immunoelectron microscopic analysis of urethral exudates from men infected with Neisseria gonorrhoeae. J Infect Dis 1996; 173:636.
  95. Giardina PC, Williams R, Lubaroff D, Apicella MA. Neisseria gonorrhoeae induces focal polymerization of actin in primary human urethral epithelium. Infect Immun 1998; 66:3416.
  96. Harvey HA, Ketterer MR, Preston A, et al. Ultrastructural analysis of primary human urethral epithelial cell cultures infected with Neisseria gonorrhoeae. Infect Immun 1997; 65:2420.
  97. Edwards JL, Brown EJ, Uk-Nham S, et al. A co-operative interaction between Neisseria gonorrhoeae and complement receptor 3 mediates infection of primary cervical epithelial cells. Cell Microbiol 2002; 4:571.
  98. Edwards JL. The role of complement in gonococcal infection of cervical epithelia. Vaccine 2008; 26 Suppl 8:I56.
  99. Edwards JL, Brown EJ, Ault KA, Apicella MA. The role of complement receptor 3 (CR3) in Neisseria gonorrhoeae infection of human cervical epithelia. Cell Microbiol 2001; 3:611.
  100. Edwards JL, Shao JQ, Ault KA, Apicella MA. Neisseria gonorrhoeae elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells. Infect Immun 2000; 68:5354.
  101. Merz AJ, So M. Interactions of pathogenic neisseriae with epithelial cell membranes. Annu Rev Cell Dev Biol 2000; 16:423.
  102. Chen T, Grunert F, Medina-Marino A, Gotschlich EC. Several carcinoembryonic antigens (CD66) serve as receptors for gonococcal opacity proteins. J Exp Med 1997; 185:1557.
  103. Gray-Owen SD, Dehio C, Haude A, et al. CD66 carcinoembryonic antigens mediate interactions between Opa-expressing Neisseria gonorrhoeae and human polymorphonuclear phagocytes. EMBO J 1997; 16:3435.
  104. Gray-Owen SD, Lorenzen DR, Haude A, et al. Differential Opa specificities for CD66 receptors influence tissue interactions and cellular response to Neisseria gonorrhoeae. Mol Microbiol 1997; 26:971.
  105. Simon D, Rest RF. Escherichia coli expressing a Neisseria gonorrhoeae opacity-associated outer membrane protein invade human cervical and endometrial epithelial cell lines. Proc Natl Acad Sci U S A 1992; 89:5512.
  106. Wang J, Gray-Owen SD, Knorre A, et al. Opa binding to cellular CD66 receptors mediates the transcellular traversal of Neisseria gonorrhoeae across polarized T84 epithelial cell monolayers. Mol Microbiol 1998; 30:657.
  107. Cannon JG, Buchanan TM, Sparling PF. Confirmation of association of protein I serotype of Neisseria gonorrhoeae with ability to cause disseminated infection. Infect Immun 1983; 40:816.
  108. Rechner C, Kühlewein C, Müller A, et al. Host glycoprotein Gp96 and scavenger receptor SREC interact with PorB of disseminating Neisseria gonorrhoeae in an epithelial invasion pathway. Cell Host Microbe 2007; 2:393.
  109. Gorby GL, Ehrhardt AF, Apicella MA, Elkins C. Invasion of human fallopian tube epithelium by Escherichia coli expressing combinations of a gonococcal porin, opacity-associated protein, and chimeric lipo-oligosaccharide. J Infect Dis 2001; 184:460.
  110. Rice PA. Molecular basis for serum resistance in Neisseria gonorrhoeae. Clin Microbiol Rev 1989; 2 Suppl:S112.
  111. Ingwer I, Petersen BH, Brooks G. Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae. J Lab Clin Med 1978; 92:211.
  112. Ram S, Cullinane M, Blom AM, et al. Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med 2001; 193:281.
  113. Ram S, McQuillen DP, Gulati S, et al. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med 1998; 188:671.
  114. Ngampasutadol J, Tran C, Gulati S, et al. Species-specificity of Neisseria gonorrhoeae infection: do human complement regulators contribute? Vaccine 2008; 26 Suppl 8:I62.
  115. Ram S, Sharma AK, Simpson SD, et al. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 1998; 187:743.
  116. Apicella MA, Mandrell RE, Shero M, et al. Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis. J Infect Dis 1990; 162:506.
  117. Apicella MA, Shero M, Jarvis GA, et al. Phenotypic variation in epitope expression of the Neisseria gonorrhoeae lipooligosaccharide. Infect Immun 1987; 55:1755.
  118. Seifert HS, Wright CJ, Jerse AE, et al. Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest 1994; 93:2744.
  119. McQuillen DP, Gulati S, Ram S, et al. Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects. J Infect Dis 1999; 179:124.
  120. Elkins C, Carbonetti NH, Varela VA, et al. Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolysaccharide is not sialylated. Mol Microbiol 1992; 6:2617.
  121. Griffiss JM, Schneider H, Mandrell RE, et al. Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane. Rev Infect Dis 1988; 10 Suppl 2:S287.
  122. Mulks MH, Plaut AG. IgA protease production as a characteristic distinguishing pathogenic from harmless neisseriaceae. N Engl J Med 1978; 299:973.
  123. Hobbs MM, Sparling PF, Cohen MS, et al. Experimental Gonococcal Infection in Male Volunteers: Cumulative Experience with Neisseria gonorrhoeae Strains FA1090 and MS11mkC. Front Microbiol 2011; 2:123.
  124. Lin L, Ayala P, Larson J, et al. The Neisseria type 2 IgA1 protease cleaves LAMP1 and promotes survival of bacteria within epithelial cells. Mol Microbiol 1997; 24:1083.
  125. Humbert MV, Awanye AM, Lian LY, et al. Structure of the Neisseria Adhesin Complex Protein (ACP) and its role as a novel lysozyme inhibitor. PLoS Pathog 2017; 13:e1006448.
  126. Rice PA, Vayo HE, Tam MR, Blake MS. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J Exp Med 1986; 164:1735.
  127. Plummer FA, Chubb H, Simonsen JN, et al. Antibodies to opacity proteins (Opa) correlate with a reduced risk of gonococcal salpingitis. J Clin Invest 1994; 93:1748.
  128. Plummer FA, Chubb H, Simonsen JN, et al. Antibody to Rmp (outer membrane protein 3) increases susceptibility to gonococcal infection. J Clin Invest 1993; 91:339.
  129. Hedges SR, Mayo MS, Mestecky J, et al. Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections. Infect Immun 1999; 67:3937.
  130. Hedges SR, Sibley DA, Mayo MS, et al. Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: effects of concomitant infections. J Infect Dis 1998; 178:742.
  131. Duncan JA, Gao X, Huang MT, et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol 2009; 182:6460.
  132. Escobar A, Candia E, Reyes-Cerpa S, et al. Neisseria gonorrhoeae induces a tolerogenic phenotype in macrophages to modulate host immunity. Mediators Inflamm 2013; 2013:127017.
  133. Johnson MB, Criss AK. Neisseria gonorrhoeae phagosomes delay fusion with primary granules to enhance bacterial survival inside human neutrophils. Cell Microbiol 2013; 15:1323.
  134. Mosleh IM, Huber LA, Steinlein P, et al. Neisseria gonorrhoeae porin modulates phagosome maturation. J Biol Chem 1998; 273:35332.
  135. Zhu W, Ventevogel MS, Knilans KJ, et al. Neisseria gonorrhoeae suppresses dendritic cell-induced, antigen-dependent CD4 T cell proliferation. PLoS One 2012; 7:e41260.
  136. Boulton IC, Gray-Owen SD. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 2002; 3:229.
  137. Pantelic M, Kim YJ, Bolland S, et al. Neisseria gonorrhoeae kills carcinoembryonic antigen-related cellular adhesion molecule 1 (CD66a)-expressing human B cells and inhibits antibody production. Infect Immun 2005; 73:4171.
  138. Liu Y, Feinen B, Russell MW. New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host. Front Microbiol 2011; 2:52.
  139. Liu Y, Islam EA, Jarvis GA, et al. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms. Mucosal Immunol 2012; 5:320.
  140. Liu Y, Russell MW. Diversion of the immune response to Neisseria gonorrhoeae from Th17 to Th1/Th2 by treatment with anti-transforming growth factor β antibody generates immunological memory and protective immunity. MBio 2011; 2:e00095.
  141. Liu Y, Liu W, Russell MW. Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells. Mucosal Immunol 2014; 7:165.
  142. Liu Y, Egilmez NK, Russell MW. Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12. J Infect Dis 2013; 208:1821.
Topic 7587 Version 32.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟